However, in response to the rapid advances in treatment and emerging therapeutic advances on the horizon it will also require fresh approaches and selleck kinase inhibitor renewed strategic thinking. Each year we have moved one step closer to achieving our collective vision of Treatment for All. Over the past five decades of the WFH’s history, there has been tremendous progress in our understanding of bleeding disorders, improvement of treatment, and enhancement of access bringing hope to patients and their families throughout the world. Nonetheless, despite our progress to date in closing the

global gap in care, our work is not complete. Too many patients remain undiagnosed and too few receive adequate treatment. The WFH remains committed to its vision of achieving Treatment for All. This paper will discuss some the historical, present and future challenges and opportunities selleck compound to close the gap in care and achieve Treatment for All. Over the past 50 years, we have seen enormous advances in treatment and therapies for bleeding disorders. Although access and availability vary widely

around the world, our understanding of coagulation mechanisms, prevention and treatment of bleeding disorders is far different than in 1963, the year the WFH was founded. It is now well established that, with proper treatment, people with haemophilia can live perfectly healthy lives. Without treatment, the reality

is that many will die young or, if they survive, suffer joint damage that leaves them with permanent disabilities. The journey to improve treatment globally began in June 1963 when Frank Schnabel, our founder and a man with severe hemophilia, convened a global meeting to establish an international haemophilia organization. There were many others involved in the early and formative years of the WFH who served either as the interim (1963) or first (1964) officers or led the medical Tryptophan synthase advisory board including: Sir Weldon Balrymple-Champneys (UK), Prof. Kenneth Brinkhous (US), Henri Chaigneau (France), Dr. Cecil Harris (Canada), Dr. E. Neumark (UK), Dr. Knut-Eric Sjolin (Denmark), Prof. J.P. Soulier (France), John Walsh (US), Dr. S. Van Creveld (The Netherlands). Mr. Schnabel’s opening words to those assembled still ring true. “The threat to the life of just one haemophiliac would be sufficient reason for us to travel to this meeting. We are here however to help the hundreds of thousands of haemophiliacs by adding another organization which can be instrumental, in liaison with national societies” [1]. What began with a meeting of representatives from 12 countries (Argentina, Australia, Belgium, Canada, Denmark, France, Germany, Japan, Netherlands, Sweden, United Kingdom and the United States) [2] has grown to become a truly global organization.